Brincker H
Acta Med Scand. 1978;204(1-2):123-8. doi: 10.1111/j.0954-6820.1978.tb08410.x.
In a placebo-controlled double-blind study the prophylactic value of oral systemic treatment with the antimycotic agent miconazole was assessed in 30 highly predisposed patients receiving intensive cytostatic chemotherapy because of haematological malignancies. Patients colonized with Candida before treatment were not freed from this micro-organism by miconazole treatment. However, only 3 out of 6 initially non-colonized miconazole-treated patients became colonized during the study, against 10 out of 10 placebo-treated patients (p = 0.036). Seven out of 15 patients in the placebo group developed clinical mycosis, against only two out of 15 in the miconazole group. The miconazole-treated patients remained clinically free of mycosis for 252 out of 264 treatment days, while the placebo-treated patients remained free of mycosis for only 263 out or 338 treatment days (p = 0.0001). The results indicate that systemic miconazole treatment protects highly predisposed patients from colonization with Candida and prevents or postpones clinically established candidosis.
在一项安慰剂对照双盲研究中，对30例因血液系统恶性肿瘤接受强化细胞抑制化疗的高危患者，评估了抗真菌药咪康唑口服全身治疗的预防价值。治疗前已被念珠菌定植的患者，咪康唑治疗未能清除该微生物。然而，在研究期间，6例初始未被定植的咪康唑治疗患者中只有3例被定植，而10例安慰剂治疗患者中有10例被定植（p = 0.036）。安慰剂组15例患者中有7例发生临床真菌病，而咪康唑组15例中只有2例。咪康唑治疗的患者在264个治疗日中有252日临床无真菌病，而安慰剂治疗的患者在338个治疗日中只有263日无真菌病（p = 0.0001）。结果表明，全身应用咪康唑治疗可保护高危患者不被念珠菌定植，并预防或推迟临床确诊的念珠菌病。
